Regencell Bioscience Holdings Ltd SEC filings RGC

Regencell Bioscience Holdings Ltd has 85 filings in SEC EDGAR's recent list, going back to Nov 13, 2020. Its latest annual report, Form 20-F, was filed on Oct 7, 2026 for the period ended Jun 30, 2026. The most recent current report (Form 6-K) was filed on May 22, 2026.

Form Description Filed Period
EFFECT Filing Jul 15, 2021 —
CERT Filing Jul 15, 2021 —
8-A12B For registration of certain classes Jul 15, 2021 —
CORRESP Letter to the SEC Jul 13, 2021 —
CORRESP Letter to the SEC Jul 13, 2021 —
CORRESP Letter to the SEC Jun 22, 2021 —
UPLOAD Letter from the SEC Jun 21, 2021 —
CORRESP Letter to the SEC Jun 11, 2021 —
UPLOAD Letter from the SEC May 3, 2021 —
CORRESP Letter to the SEC Apr 26, 2021 —
UPLOAD Letter from the SEC Apr 5, 2021 —
CORRESP Letter to the SEC Mar 22, 2021 —
UPLOAD Letter from the SEC Feb 18, 2021 —
DRS/A Filing Feb 4, 2021 —
DRSLTR Filing Feb 3, 2021 —
UPLOAD Letter from the SEC Dec 11, 2020 —
DRS Filing Nov 13, 2020 —

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
RGC (Nasdaq)
Incorporated in
Cayman Islands
Headquarters
Hong Kong
SEC filer status
Large accelerated filer
SEC CIK
1829667

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.